Novartis' AOC Therapy del-brax Shows Promising Phase I/II Results in FSHD, Marking a Quantifiable Milestone for RNA Delivery

Based on the currently disclosed trial design, this study is a typical Phase I/II randomized, double-blind, placebo-controlled trial, in which the confirmatory biomarker cohort constitutes the core analysis population. The primary endpoint is the change in plasma KHDC1L levels, used to reflect DUX4 transcriptional activity; secondary endpoints include changes in creatine kinase (CK) levels, used to assess the extent of muscle damage.

The key significance of this data lies not in whether “functional efficacy is established,” but rather in the first systematic validation of an earlier-level question: whether the DUX4 pathway can be stably suppressed. In this sense, it still pertains to mechanistic validation in the early clinical stage, but the signals are already strong enough to point toward a deeper direction of change—RNAThe Competitive Focus of Drugs Is Shifting。

The mechanism of FSHD is not inherently complex. Under normal circumstances, DUX4 is only transiently expressed during early embryonic development and is subsequently silenced long-term by epigenetic mechanisms. However, in patients with FSHD, this silencing state is lifted due to contraction of the D4Z4 repeat array or aberrant epigenetic regulation, leading to the reactivation of DUX4 in skeletal muscle.

The issue lies not in “whether to activate,” but in “how to activate.” DUX4 expression in muscle tissue exhibits distinct low-frequency, intermittent characteristics, accompanied by significant heterogeneity among different muscle fibers. This spatiotemporal instability renders the disease more akin to a system that is randomly triggered and progressively amplified, rather than a single-target disease amenable to linear control.

It is precisely for this reason that strategies indirectly regulating DUX4 via upstream pathways have consistently faced uncertainty in clinical settings. The failure of losmapimod to meet the primary endpoint in the Phase III REACH trial was not merely due to target selection bias, but rather stemmed from the following:When the disease itself exhibits strong stochastic expression characteristics, upstream interventions struggle to consistently cover the effective therapeutic window.。

In this context, the drug development pathway for FSHD is undergoing a significant shift, gradually moving from “modulating upstream signaling networks” to “directly suppressing DUX4 expression at the RNA level.”

As an siRNA therapy under the AOC platform, del-brax follows a straightforward core mechanism: reducing DUX4 mRNA levels via RNA interference to decrease the production of toxic proteins at the source.

However, the true constraint of this strategy lies not in RNAi itself, but in a more fundamental issue: whether the drug can effectively enter skeletal muscle cells after systemic administration and achieve stable release and activity within the cells.

Thus, in this disease model, a more fundamental variable begins to emerge.: The determinant of the upper limit of therapeutic efficacy is no longer just the target, but delivery.。

The core value of Antibody-Oligonucleotide Conjugates (AOCs) lies in their attempt to address the long-standing bottleneck of extrahepatic delivery of RNA therapeutics. Their basic structure consists of three components: a monoclonal antibody targeting Transferrin Receptor 1 (TfR1), a cleavable linker, and an RNA interference payload.

From a systemic perspective, AOC is not merely “siRNA conjugated with an antibody,” but rather a comprehensive reconstruction of the entire delivery cascade. The antibody mediates tissue recognition and cellular uptake, the linker determines in vivo stability and release kinetics, and the ultimate biological efficacy depends on whether this cascade can achieve sufficiently effective intracellular delivery in muscle tissue.

In other words, within the AOC framework, the true competitive variable has shifted from “sequence design capability” to “delivery system efficiency.”

From a broader perspective of the RNA therapeutic landscape, this shift is occurring synchronously across the entire field. While lipid nanoparticle (LNP) systems are highly mature for hepatic delivery, they are inherently limited by liver tropism; GalNAc-based systems have achieved remarkable success in targeting hepatocytes but remain largely confined to hepatic tissue; in contrast, the TfR1 pathway exemplified by antibody-oligonucleotide conjugates (AOCs) represents an engineered approach aimed at accessing extrahepatic tissues, such as muscle.

These technological approaches are not mutually exclusive; rather, they represent distinct engineering explorations along different dimensions to address the same challenge: how to effectively deliver RNA therapeutics beyond the liver.

The current industrial landscape related to AOC is in a transitional phase from fragmented exploration to consolidation led by platform leaders.

Through its completed 100% acquisition of Avidity Biosciences in February 2026 (valued at approximately $12 billion), Novartis has fully secured the AOC technology platform and its clinical pipeline across multiple muscular diseases, including FSHD, DM1, and DMD. This represents a typical platform-entry strategic move, rather than a single-asset enhancement.

Although Novartis has taken the lead in the AOC pathway, many other multinational pharmaceutical companies and biotechnology firms are still advancing extrahepatic RNA delivery through different technical routes, including other receptor-mediated siRNA, antibody-conjugation strategies, and gene-editing delivery systems. Overall, the industry remains in an early competitive stage with multiple pathways being validated in parallel.

Therefore, a more realistic assessment is that the core of the AOC competition is not “whether the platform is exclusive,” but rather an accelerating race in the validation speed and reproducibility of different delivery engineering pathways in real-world clinical settings.

FSHD is undergoing a highly typical shift in its R&D phase: the competitive focus is gradually transitioning from target validity to delivery system capabilities.

Although different technological approaches follow distinct pathways, the underlying challenge remains highly consistent: how to achieve effective delivery and sustained action of RNA or gene regulation tools in skeletal muscle tissue while ensuring safety.

Currently, neither the AOC platform, other receptor-targeted siRNA approaches, nor CRISPR-based epigenetic silencing strategies have established a clear dominant advantage. The industry remains in a phase of parallel validation across multiple pathways and has not yet entered a period of convergence.

From this perspective, FSHD is more akin to a “stress-testing ground for delivery systems” than a commercial sector with a clearly defined endgame structure.

FSHD itself may not become a large-scale commercial market, but its significance lies in the fact that it is becoming one of the key validation grounds for RNA therapeutics transitioning from “liver-centric delivery systems” to “extrahepatic tissue delivery systems.”

The true value of AOCs lies not in the success of any single clinical milestone, but in their ability to transform a long-standing ambiguous challenge into one that can be systematically addressed through engineering: whether drugs can be delivered stably, safely, and reproducibly to the tissues that truly require them.

And once this question begins to be systematically addressed, the competitive boundaries of the RNA therapeutics industry may also be rewritten.

Disclaimer:

The content of this article is for reference only and does not constitute investment advice. Investors who act on it do so at their own risk. The author maintains neutrality regarding the statements and opinions expressed herein and provides no express or implied warranties as to the accuracy, reliability, or completeness of the information contained. Readers are advised to use this material for reference purposes only and assume full responsibility for any consequences arising from its use.

ContactWe

The largest in China

Premier Conference in the Field of Autoimmune Drugs!

AIM 2026

Only 1 week left to register!

Scan the code to consult now

Phone: 13816031174

(Same as WeChat)

Sponsorship opportunities include, but are not limited to, speaking slots, exhibition booths, color advertisements in the conference program, dinner sponsorships, and promotional branding on conference materials.

Click here“Read Full Article”Consultation concluded!